Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660311 | 0.88 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL658499 | 0.85 | TRPV1 (0.53) | TRPV1KDM4EMAPT | |
| SCHEMBL659591 | 0.85 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL657909 | 0.85 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL658832 | 0.83 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL657356 | 0.81 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL2688130 | 0.81 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL655675 | 0.81 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL657539 | 0.80 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL658664 | 0.80 | TRPV1 (0.61) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606033-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2013-06-26 | — | — | EP | claimed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | claimed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| EP-2606033-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | TRPV1 1/4885CHRM4 229/4885KDM4E 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.